Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of Mantle Cell Lymphoma

Trial Profile

Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of Mantle Cell Lymphoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Rituximab
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 May 2016 Status changed from active, no longer recruiting to recruiting.
    • 25 May 2016 Status changed from not yet recruiting to active, no longer recruiting.
    • 19 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top